According to the accelerated clinical trial development plan (outlined by In Vivo in their presentation to investors July 2014)-the pilot clinical trial (N: 5 patients) won't be done until the end of 2015--the pivotal study (50-100 patients) won't start until 2016 (that is if the FDA agrees) and won't be completed until 2018--HDE submission would then take place in 2019--as such this stock is something that will take a very long time to reach its full potential and there are still many "roadmines" along the way that makes this a risky investment--I hope the trial is "wildly successful" and neurosurgeons are clamoring to use the scaffold ASAP but otherwise I wouldn't be looking at any miraculous rise in pps for a long time
The bowels/urinary bladder is controlled by the sacral nerves, which are below the lumbar nerves. If the spinal cord was severed at L1, that individual would lose control over their bowels/bladder, since the sacral nerves would be affected, too. So complete T11 severing would cause loss of bladder/bowel function
I greatly respect your opinions and value your comments
--would really like to know do you think that the fact that the FDA has essentially lifted most of the restrictions on this "safety" study--timeline for entry/broadening the inclusion criteria/opening the trial to 20 sites from the original 6 means that something far beyond "safety" was achieved in this first patient? Could the results have been so exempliary that the FDA wants this study done ASAP so that a scaffold + neural stem cell study can get underway?? I really believe that In Vivo has very carefully been cultivating a working relationship with the FDA and is being very cautious about saying much about the results-but the recent rise in the pps seems to suggest something more than just the lifting of the timing restrictions
"doesn't consider competition from Stem Cell developers (who may not need to use a device in tandem with their therapies"
my understanding is that they have been "plunking" stem cells into sites of ASC injury with little to no benefit (isn't this going on in China---I've read a lot about medical tourism to have this done)--I was of the understanding that the microenvironment at the site of injury is simply too "hostile" to allow these stem cells to flourish--hence the advantage of the scaffold as an "anchor"---that's why I was wondering about what CUR is doing---isn't it the same thing as just putting stem cells into the injury site as has been done unsuccessfully before??
this "telecomdomainpro" maybe immansthrope under another name--he'll be proven wrong just like his negative troll counterpart
Thanks for this post--this moronic troll has blocked me from responding to his dripple-being the low life that he is--glad I have someone else to stand up to him
The fact that the FDA is now allowing the study to be expediated tells me that the first patient surpassed the "safety" end point they were aiming for---I admire Mr. Perrin's leadership in all of this as I have said before he is cultivating a very good working relationship with the FDA and not giving into needless hype/cheerleading---this slow steady approach is what's going to win this race
Sentiment: Strong Buy
keep it up "Shortie"--have continued to add to my position on dips--your contribution to this is greatly appreciated!!!
I own CTIX but would really like to add much much more--I keep reading about "dilution" in the future?? why? What I see is a take over plain and simple---brilicidin alone is a blockbuster---you add to this the potential of Kevitrin and Purisol why would any major "player" not want to "scoop" CTIX up before it goes higher
Oh PLEASE keep up the negative comments-"Shortie" will buy more on any dips--have already done real well with ONCS--your comments will make me even more money!!!
Gee I guess you were wrong??
thanks again "Shortie"---loaded right up Dec 5 (actually 20K beyond the 5K I bought in the AM)
--now Dec 8 I'm laughing all the way to the bank!!!
Please give me some more of your "great" advice!!!
Sentiment: Strong Buy
there won't be anywhere near the time it took to enroll the first patient---the criteria for entry have been expanded--both in age (up to 65) and area of injury--once that second patient confirms "safety" In Vivo will approach the FDA about expediating the trial so that the remaining 3 patients who will take part in this trial don't have to be done sequentially but could be done simultaneously if deemed possible
Thousands of patients die each year from antibiotic resistant infections--CTIX will soon offer something that can completely change that---quit "bashing" this company and the hope for many patients
I also sincerely believe the results will be good---but if not you may have to reconsider your destination---?1000 islands in Eastern Lake Ontario-Oswego NY?
Sentiment: Strong Buy
I'm wondering if "effective money raising strategies" may also mean being bought out by a much bigger player (?J & J/Stryker etc)--if that occurs the road to commercialization could be much faster.